Table 1. Demographic and clinical characteristics of patients with CSU (n=90).
| Parameter | Value | |
|---|---|---|
| Age (yr) | 44.41±15.11 | |
| Sex | ||
| Male | 39 (43.3) | |
| Female | 51 (56.7) | |
| Duration of CSU (mo) | 12.0 (4.0–36.0) | |
| Interval of omalizumab | ||
| 4 wk | 89 (98.9) | |
| 8 wk | 1 (1.1) | |
| Dosage of omalizumab | ||
| 150 mg | 87 (96.7) | |
| 300 mg | 3 (3.3) | |
| Thyroid disease | 7 (7.8) | |
| Angioedema | 20 (22.2) | |
| NSAID exacerbation | 8 (8.9) | |
| Lab findings | ||
| Total IgE (IU/ml) | 154.00 (54.00–254.00) | |
| ANA positivity (≥1:80) | 20 (22.2) | |
| TFT abnormality | 11 (12.2) | |
| ECP (µg/L) | 17.80 (11.60–30.80) | |
| Severity (Initial) | ||
| Well-controlled (0≤UAS7<7) | 0 (0.0) | |
| Mild (7≤UAS7<16) | 3 (3.3) | |
| Moderate (16≤UAS7<28) | 41 (45.6) | |
| Severe (28≤UAS7≤42) | 46 (51.1) | |
| Response | ||
| Responder group | 78 (86.7) | |
| Non-responder group | 12 (13.3) | |
Values are presented as number only, number (%), mean ± standard deviation, or median (Q1–Q3).
CSU: chronic spontaneous urticaria, NSAID: non-steroidal anti-inflammatory drug, ANA: antinuclear antibody, TFT: thyroid function test, ECP: eosinophil cationic protein, UAS7: Urticaria Activity Score summed over 7 days.